<unk>  is an antineoplastic agent that is FDA approved for the treatment of palliative management of gastrointestinal adenocarcinoma metastatic to the liver.   Common adverse reactions include nausea, vomiting, diarrhea, enteritis, stomatitis and localized erythema.  The more common laboratory abnormalities are anemia, leukopenia, thrombocytopenia and elevations of alkaline phosphatase, serum transaminase, serum bilirubin and lactic dehydrogenase..
Floxuridine
Idoxuridine
Trifluridine
Decitabine
Vidarabine
Nelarabine
Fludarabine 
Mafosfamide